A novel virally inactivated human platelet lysate preparation rich in TGF-β, EGF and IGF, and depleted of PDGF and VEGF

Pierre Alain Burnouf, Po Kai Juan, Chen Yao Su, Ya Po Kuo, Ming Li Chou, Ching Hua Su, Yu Hung Tseng, Che Tong Lin, Thierry Burnouf

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

There is emerging interest in the use of standardized virally inactivated human platelet lysate preparations rich in GFs (growth factors) for cell cultures, cell therapy and clinical applications. In the present paper, we report a simple process to prepare a virally inactivated platelet lysate preparation rich in TGF-β1 (transforming growth factor-β1), EGF (epidermal growth factor) and IGF (insulin-like growth factor) and depleted of PDGF (platelet-derived growth factor) and VEGF (vascular endothelial growth factor). Apheresis platelet concentrates were treated by the S/D (solvent/detergent) viral inactivation procedure, then subjected to an oil extraction followed by adsorption with activated charcoal and finally sterile-filtered. The resulting preparation contained a mean of 368.4, 2.4 and 54.7 ng/ml of TGF-β1, EGF and IGF respectively. PDGF-AB and VEGF were essentially completely removed by the charcoal treatment. The mean albumin, IgG, IgM and IgA and fibrinogen contents were approx. 40.0, 8.5, 0.87, 1.66 and 2.65 mg/ml respectively, cholesterol and triglycerides were at 15 and 20.7 mg/ml respectively and TnBP (tri-n-butyl phosphate) and Triton X-45 were at 8.7 and 8.8 p.p.m. respectively. Supplementing MEM (minimum essential medium) with 1-10% of this S/D-treated platelet lysate promoted the proliferation of MG63 and SIRC cell lines as well as, or better than, 10% (v/v) FBS (fetal bovine serum), as based on the MTS [3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4- sulfophenyl)-2H-tetrazolium] assay. The process used to prepare such S/D-treated platelet lysates is easily scalable for industrial production. Our results open up the possibility to evaluate the potential of this new preparation for stem cell expansion and/or bone tissue engineering and regeneration.

Original languageEnglish
Pages (from-to)151-160
Number of pages10
JournalBiotechnology and Applied Biochemistry
Volume56
Issue number4
DOIs
Publication statusPublished - Aug 2010

Fingerprint

Insulin
Platelet-Derived Growth Factor
Somatomedins
Platelets
Epidermal Growth Factor
Vascular Endothelial Growth Factor A
Blood Platelets
Detergents
Charcoal
Transforming Growth Factors
Virus Inactivation
Tissue regeneration
Blood Component Removal
Bone Regeneration
Octoxynol
Tissue Engineering
Cell- and Tissue-Based Therapy
Stem cells
Tissue engineering
Cell culture

Keywords

  • Fetal bovine serum (FBS)
  • Growth factor
  • Lysate
  • Platelet
  • Solvent/detergent
  • Stem cell

ASJC Scopus subject areas

  • Drug Discovery
  • Applied Microbiology and Biotechnology
  • Biomedical Engineering
  • Process Chemistry and Technology
  • Bioengineering
  • Molecular Medicine
  • Biotechnology

Cite this

A novel virally inactivated human platelet lysate preparation rich in TGF-β, EGF and IGF, and depleted of PDGF and VEGF. / Burnouf, Pierre Alain; Juan, Po Kai; Su, Chen Yao; Kuo, Ya Po; Chou, Ming Li; Su, Ching Hua; Tseng, Yu Hung; Lin, Che Tong; Burnouf, Thierry.

In: Biotechnology and Applied Biochemistry, Vol. 56, No. 4, 08.2010, p. 151-160.

Research output: Contribution to journalArticle

Burnouf, Pierre Alain ; Juan, Po Kai ; Su, Chen Yao ; Kuo, Ya Po ; Chou, Ming Li ; Su, Ching Hua ; Tseng, Yu Hung ; Lin, Che Tong ; Burnouf, Thierry. / A novel virally inactivated human platelet lysate preparation rich in TGF-β, EGF and IGF, and depleted of PDGF and VEGF. In: Biotechnology and Applied Biochemistry. 2010 ; Vol. 56, No. 4. pp. 151-160.
@article{b4394edac6a74f9a9c2ad409ad31ad9a,
title = "A novel virally inactivated human platelet lysate preparation rich in TGF-β, EGF and IGF, and depleted of PDGF and VEGF",
abstract = "There is emerging interest in the use of standardized virally inactivated human platelet lysate preparations rich in GFs (growth factors) for cell cultures, cell therapy and clinical applications. In the present paper, we report a simple process to prepare a virally inactivated platelet lysate preparation rich in TGF-β1 (transforming growth factor-β1), EGF (epidermal growth factor) and IGF (insulin-like growth factor) and depleted of PDGF (platelet-derived growth factor) and VEGF (vascular endothelial growth factor). Apheresis platelet concentrates were treated by the S/D (solvent/detergent) viral inactivation procedure, then subjected to an oil extraction followed by adsorption with activated charcoal and finally sterile-filtered. The resulting preparation contained a mean of 368.4, 2.4 and 54.7 ng/ml of TGF-β1, EGF and IGF respectively. PDGF-AB and VEGF were essentially completely removed by the charcoal treatment. The mean albumin, IgG, IgM and IgA and fibrinogen contents were approx. 40.0, 8.5, 0.87, 1.66 and 2.65 mg/ml respectively, cholesterol and triglycerides were at 15 and 20.7 mg/ml respectively and TnBP (tri-n-butyl phosphate) and Triton X-45 were at 8.7 and 8.8 p.p.m. respectively. Supplementing MEM (minimum essential medium) with 1-10{\%} of this S/D-treated platelet lysate promoted the proliferation of MG63 and SIRC cell lines as well as, or better than, 10{\%} (v/v) FBS (fetal bovine serum), as based on the MTS [3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4- sulfophenyl)-2H-tetrazolium] assay. The process used to prepare such S/D-treated platelet lysates is easily scalable for industrial production. Our results open up the possibility to evaluate the potential of this new preparation for stem cell expansion and/or bone tissue engineering and regeneration.",
keywords = "Fetal bovine serum (FBS), Growth factor, Lysate, Platelet, Solvent/detergent, Stem cell",
author = "Burnouf, {Pierre Alain} and Juan, {Po Kai} and Su, {Chen Yao} and Kuo, {Ya Po} and Chou, {Ming Li} and Su, {Ching Hua} and Tseng, {Yu Hung} and Lin, {Che Tong} and Thierry Burnouf",
year = "2010",
month = "8",
doi = "10.1042/BA20100151",
language = "English",
volume = "56",
pages = "151--160",
journal = "Biotechnology and Applied Biochemistry",
issn = "0885-4513",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - A novel virally inactivated human platelet lysate preparation rich in TGF-β, EGF and IGF, and depleted of PDGF and VEGF

AU - Burnouf, Pierre Alain

AU - Juan, Po Kai

AU - Su, Chen Yao

AU - Kuo, Ya Po

AU - Chou, Ming Li

AU - Su, Ching Hua

AU - Tseng, Yu Hung

AU - Lin, Che Tong

AU - Burnouf, Thierry

PY - 2010/8

Y1 - 2010/8

N2 - There is emerging interest in the use of standardized virally inactivated human platelet lysate preparations rich in GFs (growth factors) for cell cultures, cell therapy and clinical applications. In the present paper, we report a simple process to prepare a virally inactivated platelet lysate preparation rich in TGF-β1 (transforming growth factor-β1), EGF (epidermal growth factor) and IGF (insulin-like growth factor) and depleted of PDGF (platelet-derived growth factor) and VEGF (vascular endothelial growth factor). Apheresis platelet concentrates were treated by the S/D (solvent/detergent) viral inactivation procedure, then subjected to an oil extraction followed by adsorption with activated charcoal and finally sterile-filtered. The resulting preparation contained a mean of 368.4, 2.4 and 54.7 ng/ml of TGF-β1, EGF and IGF respectively. PDGF-AB and VEGF were essentially completely removed by the charcoal treatment. The mean albumin, IgG, IgM and IgA and fibrinogen contents were approx. 40.0, 8.5, 0.87, 1.66 and 2.65 mg/ml respectively, cholesterol and triglycerides were at 15 and 20.7 mg/ml respectively and TnBP (tri-n-butyl phosphate) and Triton X-45 were at 8.7 and 8.8 p.p.m. respectively. Supplementing MEM (minimum essential medium) with 1-10% of this S/D-treated platelet lysate promoted the proliferation of MG63 and SIRC cell lines as well as, or better than, 10% (v/v) FBS (fetal bovine serum), as based on the MTS [3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4- sulfophenyl)-2H-tetrazolium] assay. The process used to prepare such S/D-treated platelet lysates is easily scalable for industrial production. Our results open up the possibility to evaluate the potential of this new preparation for stem cell expansion and/or bone tissue engineering and regeneration.

AB - There is emerging interest in the use of standardized virally inactivated human platelet lysate preparations rich in GFs (growth factors) for cell cultures, cell therapy and clinical applications. In the present paper, we report a simple process to prepare a virally inactivated platelet lysate preparation rich in TGF-β1 (transforming growth factor-β1), EGF (epidermal growth factor) and IGF (insulin-like growth factor) and depleted of PDGF (platelet-derived growth factor) and VEGF (vascular endothelial growth factor). Apheresis platelet concentrates were treated by the S/D (solvent/detergent) viral inactivation procedure, then subjected to an oil extraction followed by adsorption with activated charcoal and finally sterile-filtered. The resulting preparation contained a mean of 368.4, 2.4 and 54.7 ng/ml of TGF-β1, EGF and IGF respectively. PDGF-AB and VEGF were essentially completely removed by the charcoal treatment. The mean albumin, IgG, IgM and IgA and fibrinogen contents were approx. 40.0, 8.5, 0.87, 1.66 and 2.65 mg/ml respectively, cholesterol and triglycerides were at 15 and 20.7 mg/ml respectively and TnBP (tri-n-butyl phosphate) and Triton X-45 were at 8.7 and 8.8 p.p.m. respectively. Supplementing MEM (minimum essential medium) with 1-10% of this S/D-treated platelet lysate promoted the proliferation of MG63 and SIRC cell lines as well as, or better than, 10% (v/v) FBS (fetal bovine serum), as based on the MTS [3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4- sulfophenyl)-2H-tetrazolium] assay. The process used to prepare such S/D-treated platelet lysates is easily scalable for industrial production. Our results open up the possibility to evaluate the potential of this new preparation for stem cell expansion and/or bone tissue engineering and regeneration.

KW - Fetal bovine serum (FBS)

KW - Growth factor

KW - Lysate

KW - Platelet

KW - Solvent/detergent

KW - Stem cell

UR - http://www.scopus.com/inward/record.url?scp=77956380287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956380287&partnerID=8YFLogxK

U2 - 10.1042/BA20100151

DO - 10.1042/BA20100151

M3 - Article

C2 - 20608898

AN - SCOPUS:77956380287

VL - 56

SP - 151

EP - 160

JO - Biotechnology and Applied Biochemistry

JF - Biotechnology and Applied Biochemistry

SN - 0885-4513

IS - 4

ER -